MAP2K7 and hepatocellular carcinoma: To investigate whether DCP and Sorafenib are acting on HCC through the Raf/MEK/ERK kinases, we treated HLE cells with Sorafenib, DCP, or concomitantly with DCP and Sorafenib for 24 h and monitored the expression levels of Raf, MEK and ERK by Western blot analysis.